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Abstract
Epidemic Clostridium difficile (027/BI/NAP1) rapidly emerged in the past decade as the leading
cause of antibiotic-associated diarrhea worldwide. However, the key moments in the evolutionary
history leading to its emergence and subsequent patterns of global spread remain unknown. Here
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we define the global population structure of C. difficile 027/BI/NAP1 based on whole-genome
sequencing and phylogenetic analysis. We demonstrate that two distinct epidemic lineages, FQR1
and FQR2, not one as previously thought, emerged in North America within a relatively short
period after acquiring the same fluoroquinolone resistance mutation and a highly-related
conjugative transposon. The two epidemic lineages displayed distinct patterns of global spread,
and the FQR2 lineage spread more widely leading to healthcare outbreaks in the UK, continental
Europe and Australia. Our analysis identifies key genetic changes linked to the rapid trans-
continental dissemination of epidemic C. difficile 027/BI/NAP1 and highlights the routes by
which it spreads through the global healthcare system.
Clostridium difficile is the most common infectious cause of antibiotic-associated diarrhea
and healthcare infection in the developed world1,2. Antibiotic treatment and hospitalization
are major risk factors for C. difficile colonization leading to asymptomatic carriage,
diarrhea, pseudomembraneous colitis or death3. C. difficile pathogenesis is associated with
the production of the enterotoxins TcdA and TcdB that are encoded within a pathogenicity
locus (PaLoc)4. C. difficile produces highly resistant and infectious spores, which promote
environmental transmission within the healthcare setting5, and potentially facilitate spread
over greater distances by those in the carrier state6.
The global emergence of C. difficile infection (CDI) in the past decade followed highly-
publicized C. difficile outbreaks in the USA7 and Canada8 that were associated with
increased rates of disease recurrence and mortality7-10. The outbreaks were caused by a
previously uncommon, fluoroquinolone resistant variant of C. difficile genotyped as 027/BI/
NAP17,8. Fluoroquinolone resistant (FQR) C. difficile 027/BI/NAP1 is still the most
common variant causing CDI throughout North America11. During 2004-2006 there were
severe C. difficile 027/BI/NAP1 outbreaks in the UK and in subsequent years FQR C.
difficile 027/BI/NAP1 accounted for >40% of cases UK-wide12, and is now commonly
found in continental Europe13,14 and more recently in Australia15. Although FQR C.
difficile 027/BI/NAP1 is widespread in healthcare facilities worldwide the underlying
reasons for its rapid emergence and the subsequent patterns of global spread remain
unknown.
To address these questions, we sequenced the genomes of a global collection of C. difficile
027/BI/NAP1 (n=151) isolated primarily from hospital patients between 1985 and 2010
(Supplementary Table 1). Illumina reads were aligned to the genome of the C. difficile 027/
BI/NAP1 strain R2029116. We identified a total of 3,686 single nucleotide polymorphisms
(SNPs) within the 3.8 Mb non-repetitive, core genome (representing 95% of genome). Of
these, 3,150 (85%) of the SNPs were clustered and private to 8 individual isolates,
suggesting that these genomic regions were imported from outside the 027/BI/NAP1 lineage
(Supplementary Fig. 1; Supplementary Note). These SNPs were removed as they could
mask the true phylogenetic signal, leaving 536 SNPs for downstream phylogenetic analysis.
Other than these events, homologous recombination has not played a major role in shaping
the phylogeny of the global C. difficile 027/BI/NAP1 collection (Supplementary Fig. 2;
Supplementary Note).
Figure 1a shows a maximum-likelihood phylogeny representing the C. difficile 027/BI/
NAP1 global population structure. The phylogeny discriminates between >100 distinct
genotypes within the global collection and shows limited geographical clustering, implying
frequent, long-range transmission between humans, and in a limited number of cases two-
way transmission between human and animal or food sources (Supplementary Note). The
core genome of C. difficile 027/BI/NAP1 exhibits a relatively low-level of genetic diversity,
consistent with its recent emergence, with very few SNPs defining the major branches in the
phylogeny (Supplementary Fig. 3). Using three methods, we estimated the mutation rate of
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C. difficile 027/BI/NAP1 to be 1.47×10−7-5.33×10−7 (95% confidence intervals)
substitutions per site per year, equivalent to 1-2 mutations per genome per year
(Supplementary Fig. 4; Supplementary Table 2; Supplementary Note). Interestingly, this rate
is ~10 times slower than Streptococcus pneumoniae17 and Staphylococcus aureus18 over
similar timescales and may be due to the fact that metabolically dormant spores do not
accumulate mutations19.
Importantly, the global phylogeny demonstrates the presence of two genetically distinct
lineages which have independently acquired an identical mutation (Thr82Ile) in DNA gyrase
subunit A (gyrA), by either mutation or recombination, leading to high-level FQR20 (Fig. 1).
Although both lineages share this mutation, which is the most frequent in FQR isolates20,
both lineages are highly supported by maximum-likelihood and Bayesian methods
(Supplementary Figs. 3, 5), unequivocally demonstrating that FQR has arisen in two
epidemic C. difficile 027/BI/NAP1 lineages in two separate events. We named these
lineages FQR1 and FQR2. Bayesian analysis estimates that FQR1 and FQR2 have emerged
recently, with most recent common ancestors in ~1993 and ~1994, respectively (median
estimates; 95% highest posterior density intervals are 1984-1999 for FQR1 and 1986-1999
for FQR2). Near the base of the C. difficile 027/BI/NAP1 phylogeny and outside of both
FQR lineages are isolates from various global locations (Singapore, Japan, Korea, Canada,
the USA, the UK, Germany and France) and sampling times (1985-2009). To our
knowledge, none of the isolates in this part of the phylogeny are associated with major
hospital outbreaks, suggesting that these isolates represent the pre-epidemic C. difficile 027/
BI/NAP1 genetic background from which FQR epidemic lineages emerged.
Lineage FQR1 contains epidemic isolates associated with healthcare outbreaks in the USA
(Pennsylvania (2001), Oregon (2003), New Jersey (2004), Arizona (2006 and 2007) and
Maryland (2007))7 and isolates associated with sporadic infections in South Korea21 and
Switzerland between 2007 and 2010. Bayesian phylogeographic analysis22 indicates that the
FQR1 lineage originated from the USA (99% probability). The earliest isolate in the FQR1
lineage is from Pittsburgh, Pennsylvania in 2001, representing one of the earliest reports of
an increase in CDI caused by FQR C. difficile 027/BI/NAP19,23. Thus, FQR1 appears to
represent an epidemic lineage that originally emerged in the North East of the USA and
subsequently transmitted to South Korea and Switzerland.
The FQR2 lineage contains the majority of epidemic isolates that are widely spread
geographically (Figure 1a). The most striking feature in FQR2 is a star-like topology in the
early part of the lineage generally consistent with rapid population expansion from a
common progenitor (Supplementary Fig. 5). Two isolates in our collection were found on
the node at the base of the star-like topology, one associated with an outbreak in Montreal in
200324 and the other from the Netherlands in 2006. Bayesian analysis suggests the FQR2
lineage also originated in North America (with 59% probability from the USA and 33%
probability from Canada). Interestingly, all but one Canadian isolates found in this lineage
were from Montreal where FQR C. difficile 027/BI/NAP1 outbreaks were initially reported
in Canada8,10.
The Bayesian phylogeny25 contains multiple highly-supported sub-lineages of FQR2
associated with distinct geographic locations suggesting rapid trans-continental
dissemination from North America to continental Europe, the UK and Australia. Our
analysis demonstrates a single introductory event of FQR2 into Australia and at least four
separate introductions into continental Europe, including two trans-Atlantic transmission
events (one of which reached the Netherlands) and two from the UK, giving rise to present-
day isolates in Austria and Poland26 (Fig. 2a; Supplementary Fig. 5). Similarly, the
descendants of FQR2 were introduced into the UK on at least four occasions, including three
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trans-Atlantic transmission events from North America and one from continental Europe,
leading to a series of highly-publicized outbreaks in UK hospitals during 2004-200627.
To investigate the introduction and subsequent spread of C. difficile 027/BI/NAP1 within
the UK we analyzed the genomes of a collection of a further 145 UK isolates from
healthcare patients (Supplementary Table 3) (in addition to the 43 UK isolates in our global
collection). A maximum-likelihood phylogeny (Fig. 1b) demonstrates that long-range
geographical transmission was frequent and extensive within the UK (Fig. 2b). This
collection confirms that FQR2 C. difficile 027/BI/NAP1 likely reached the UK on at least
four separate occasions, arriving independently in Exeter, Ayrshire, and Birmingham from
North America and arriving in Maidstone from continental Europe (Fig. 1b and Fig. 2b).
The introduction into the Maidstone area likely triggered a large-scale hospital outbreak that
affected London and Cambridge27. Despite multiple introductions, the majority of present-
day UK isolates (including those from Liverpool, Belfast, Birmingham, London, Cambridge,
Exeter and multiple sites in Scotland) are descendants of one sub-lineage whose earliest
representative in our collection is a 2002 Birmingham isolate. This dominant sub-lineage
also underlies the Stoke Mandeville outbreak27 (Fig. 1b and Fig. 2b).
The emergence of epidemic C. difficile 027/BI/NAP1 has been proposed to be due to
genetic changes in the tcdC gene of the PaLoc4,7,8,28. However, we discovered only 2 SNPs
in the entire 19.6 kb PaLoc region in our 027/BI/NAP1 collection, both private to a single
isolate. Consistent with a previous proposal based on two C. difficile 027/BI/NAP1
genomes16, there is no change within the entire PaLoc region between pre- and post-
epidemic isolates of C. difficile 027/BI/NAP1 that could explain the emergence
(Supplementary Note). As described above, we provide strong evidence that the acquisition
of FQR in two distinct lineages is associated with the emergence of C. difficile 027/BI/
NAP1. We next determined if there are other genetic changes linked to the acquisition of
FQR that could underlie a presumed increase of fitness contributing to the emergence of
FQR1 and FQR2. Only 2 and 7 SNPs define the branches leading to lineages FQR1 and
FQR2, respectively. However, besides the gyrA mutation (Figure 1) there are no SNPs
shared by both lineages (Supplementary Table 4). Further, there is little evidence that a
significant change in phenotype could result from any of the SNPs that define the FQR1 and
FQR2 lineages (Supplementary Table 4; Supplementary Note), except perhaps the gyrA
mutation itself. Besides these SNPs and the gyrA mutation we also identified 10 non-
synonymous SNPs conflicting with the phylogeny (homoplasic, 1.9% of the total number)
that are present mainly within FQR1 and FQR2. These 10 SNPs affect 8 genes associated
with antimicrobial resistance or cell surface modification (Table 1; Supplementary Fig. 3;
Supplementary Note). However, these SNPs are only present within a small fraction of the
FQR1 and FQR2 isolates so their presence cannot explain the emergence of C. difficile 027/
BI/NAP1.
Horizontal gene transfer is a key mechanism driving C. difficile evolution29,30. We therefore
assembled the C. difficile 027/BI/NAP1 genomes and identified widespread acquisition of a
range of mobile elements associated with erythromycin, chloramphenicol, tetracycline and
aminoglycoside resistance throughout the phylogeny (Supplementary Fig. 3; Supplementary
Note). Importantly, we found a class of CTn5-like elements29 in almost all isolates in FQR1
and FQR2 lineages, where they are inserted in the same genome location in the majority of
isolates (Supplementary Fig. 6; Supplementary Note). The FQR1 and FQR2 lineages both
share a common CTn5-like element, which we named Tn6192, that contains genes encoding
an ABC transport system, a two-component transcriptional regulator and a predicted DNA-
binding protein (Supplementary Table 5). The version found in the FQR2 lineage differs
from that in the FQR1 lineage by harboring a contiguous insertion of 15.7 kb, Tn610531,
which contains 14 genes, four of which are predicted to be DNA-binding proteins or
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transcriptional regulators (Supplementary Table 5). This element has also acted as a hot-spot
for further integrations throughout the FQR2 lineage (Supplementary Fig. 6). The presence
of Tn6192 is the only other significant genetic trait, aside from the fluoroquinolone
resistance SNP, that differentiates FQR1 and FQR2 from the pre-epidemic isolates
(Supplementary Table 6). It is unknown whether the genes carried by this element have any
phenotypic effect on the core genome. However, Tn6192 may have played a role in the
success of these lineages.
We demonstrate that the separate acquisitions of FQR and a conjugative transposon in two
distinct lineages of C. difficile 027/BI/NAP1 are the key genetic changes linked to its rapid
emergence during the early 2000s7,8. Further, our data suggest that the acquisition of
resistance to commonly used antibiotics is a major feature of the continued evolution and
persistence of C. difficile 027/BI/NAP1 in the healthcare settings. It is notable that
fluoroquinolone antibiotics were one of the most commonly prescribed antibiotic classes in
North America during the late 1990s and early 2000s32, so it is during this time that the
selective pressure for the acquisition and maintenance of FQR within healthcare settings
would have been at its highest, explaining the near simultaneous emergence of more than
one clone of FQR C. difficile 027/BI/NAP1. We also demonstrate the ease and rapidity with
which FQR C. difficile 027/BI/NAP1 has transmitted internationally highlighting the
interconnectedness of the global healthcare system facilitated by rapid human travel. Whole-
genome sequencing and phylogenetic analysis has been used successfully for clinical
transmission studies of methicillin resistant S. aureus within a hospital33 and although the
low mutation rate may pose some limitations we believe this approach will have great
potential for C. difficile. Our analysis provides a genomic framework for understanding the
population structure, geographical source, epidemiology and evolution of this highly
transmissible healthcare pathogen.
Online Methods
C. difficile strain collection
The C. difficile isolates chosen for this study were characterized as PCR-ribotype 027 or
176, REA type BI or PFGE type NAP1 and include 151 isolates from a global collection and
188 isolates from the UK, with an overlap of 43 isolates between the collections. The global
collection includes 25 isolates from two previous studies16,30. New genome sequencing data
was generated for 6 of these isolates. Supplementary Table 1 and Supplementary Table 3
summarize the isolate details. Genomic DNA was extracted as previously described30.
Sequencing, mapping, and SNP detection
Paired-end multiplex libraries were created as described18, followed by sequencing on
Illumina GAIIx and HiSeq2000 platforms. The read length was 54 bp for samples Liv1-
Liv21, 108 bp for samples Gla001-Gla022, and 76 bp for the rest. All isolates were
sequenced to an average coverage of 110-fold across the isolates. Sequencing reads were
aligned with BWA34 against the genome sequence of the ribotype 027 reference strain
R2029116. SNPs were identified with SAMtools35. A coverage cut-off of >5-fold and <three
times the average coverage was set for each individual isolate during SNP detection.
Repetitive regions in the reference genome sequence were characterized using REPuter36
and the repeat finder functions in the MUMmer package37. The boundaries of repetitive
regions were extended to include the mobile elements in R20291. SNPs falling within these
repetitive regions were excluded. To confirm the alleles for each variant position, SNPs
were checked at each position in all sequencing reads in all isolates. An allele was only
considered to be valid if supported by all reads (if 5<coverage<=40) or >92.5% of the total
reads (if coverage >40) covering the position; otherwise it was treated as missing data. Our
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method allows no false positive SNPs and a false negative rate of ~8% (Supplementary Fig.
7; Supplementary Note).
Phylogenetic analysis
An appropriate evolutionary model (simple GTR) was determined using jModelTest 0.1.138.
Phylogenetic relationships were inferred using three methods: 1), split-decomposition and
neighbor-net methods in SplitsTree439; 2), the program PHYML40, and 3), the program
BEAST25. In the first two cases, a simple GTR model was used. Neighbor-joining tree
(Supplementary Fig. 2b) were also constructed with PHYML, and the results were
compared. Two non-027/BI/NAP1 C. difficile isolates 63029 and CF530 were used to root
the global phylogeny.
In the BEAST analysis, three clock models (strict, relaxed lognormal and relaxed
exponential) and two population models (constant and skyline) were tested initially. The
relaxed exponential clock model in combination with skyline population model was
determined as more suitable based on Bayes Factor calculations41 and was used for later
BEAST runs. The program was specified to estimate tMRCA (time to the most recent
common ancestor) of taxon groupings. All other parameters were set to default. These
analyses were carried out with a chain length of 400,000,000 states, and re-sampling every
20,000 states. The phylogeograpic history was also inferred with BEAST using a Bayesian
method as described22. The ESS values were >200 for all parameters.
Accessory genome
For each genome, the unaligned sequencing reads were assembled using Velvet42. To assess
whether the resulting contigs were unique, each contig with a length >1kb was searched
using BLASTN against the current pan-genome, which was made by concatenating the draft
genome sequence of M7404 and already determined unique contigs. Any unique contigs
were added to the pan-genome. If the match was of >80% identity and covered >40% of the
contig length, this contig was not considered to be unique, and was not added to the current
pan-genome. The resulting unique contigs were individually searched against the NCBI
bacterial genome database to check for contamination. The filtered unique contigs were
added to the genome sequence of M7404 to create a pan-genome. Finally, the sequencing
reads from each strain were aligned against the constructed pan-genome to assess for the
presence and absence of genomic regions in each isolate. The raw Illumina data were also
assembled de novo. Draft genome sequences were produced for isolates by ordering contigs
against a suitable reference sequence. Pairwise genome comparisons were made in Artemis
Comparison Tool43. Key mobile elements and their nomenclature are described in
Supplementary Note.
Identification of homoplasic characters and homologous recombination
Homoplasic SNPs were identified by examining the SNP allele pattern across all isolates in
relation to the phylogenetic tree. A SNP was considered homoplasic if the allele pattern did
not agree with the tree topology. Genomic regions affected by homologous recombination
were identified by a) clusters of SNPs within 2,000 bp windows and b) an iterative method
to eliminate recombination sites as described17 The identified homologous recombination
blocks were excluded from phylogenetic and population genetic analysis.
Mutation rate
The apparent mutation rate was estimated using three methods: 1), A full maximum-
likelihood model assuming a rapid expansion which results in perfect star genealogies,
implemented in an R script44 (Supplementary Note; Supplementary Fig. 8); 2), the program
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BEAST25; and 3), the program Path-O-Gen v1.3 (See URL). A maximum-likelihood tree
was used in this analysis. BEAST analyses were carried out as stated above. The dataset
used for 2) and 3) is the final SNP alignment of the global collection. A final mutation rate
was determined by combining the single estimate from method 3) and 95% confidence
intervals from methods 1) and 2)45.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Phylogeny of C. difficile 027/BI/NAP1 based on core genome SNPs. a, Global phylogeny
(n=151 isolates). Colored nodes indicate the geographical source of the isolates. The
position of the inferred root is indicated by a dashed line. b, Phylogeny of UK isolates
(n=188) colored according to geographical source of isolates (gray - non-UK isolates).
Dashed-line circled areas indicate the isolates with Thr82Ile substitution in gyrA associated
with fluoroquinolone resistance. Black arrows show insertion of selected mobile elements.
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Transmission events inferred for epidemic C. difficile 027/BI/NAP1. a, Global spread of
lineages FQR1 (red arrows) and FQR2 (blue arrows) inferred from phylogeographic analysis
(Supplementary Fig. 5). Global map demonstrating the countries where fluoroquinolone-
resistant (pink) and fluoroquinolone-sensitive (yellow) C. difficile 027/BI/NAP1 has been
reported6. Width of the arrow is approximately proportional to the number of descendents
from each sub-lineage. b, Inferred arrivals (blue dashed arrows) and transmissions (red
arrows) of FQR2 into and within the UK based on phylogeographic analysis (Supplementary
Fig. 5) and maximum likelihood phylogeny (Fig. 1b).
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Table 1
Non-synonymous homoplasic SNPs identified in the core genomes of C. difficile 027/BI/NAP1 isolates. The
positions refer to those in the R20291 genome. The alleles listed relate to the forward strand.
Position Region SNP Substitution Antibiotic
5420





DNA gyrase subunit A




















T Pro538Leu Fusidic acid
1800920
two-component
response regulator 31G>A Glu11Lys
1802086
two-component sensor
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